Monday, March 30, 2020
JW Holdings Acquires U.S. Patent on Its Technology for Early Diagnosis of Pancreatic Cancer
An Innovative Diagnostic Platform
JW Holdings Acquires U.S. Patent on Its Technology for Early Diagnosis of Pancreatic Cancer
  • By Choi Moon-hee
  • February 18, 2020, 11:14
Share articles

JW Holdings has obtained a U.S. patent for its multiple biomarker diagnostic kit that can detect pancreatic cancer early through a simple blood test.

JW Holdings announced on Feb. 17 that it has obtained a patent from the U.S. Patent and Trademark Office (USPTO) for its technology to produce the world's first multiple biomarker diagnostic kit that can detect pancreatic cancer early through a simple blood test.


The company has developed an innovative diagnostic platform that enables the screening of cancer by stages by simultaneously using substances obtained from a patient in early and late stages of pancreatic cancer. The company acquired the technology from Professor Baek Yung-ki of Yonsei University in 2017.

Until now, doctors have used a method to test CA19-9, a cancer-specific antigen that responds mainly in patients with late-stage pancreatic cancer. The diagnostic kit is the industry’s first product that diagnoses pancreatic cancer using complement factor B (CFB), which is found in early-stage patients.

JW Holdings registered its patent in Japan (2018), China, and Europe (2019), following Korea in 2016.

JW Holdings is currently developing a multi-biomarker diagnostic kit and a diagnostic algorithm including CFB and CA19-9, through its subsidiary JW Bioscience. In addition, this year, it will conduct exploratory clinical trials on 500 patients including pancreatic cancer patients with a research team led by Kang Chang-moo at Shinchon Severance Hospital.